Cysview is a special medication that reacts with bladder cancer causing it to become more visible to the doctor when they look in the bladder with a blue light scope. A white light setting is used to illuminate the bladder during a routine cystoscopy, and a blue light setting (to induce and view fluorescence in cancerous tissue, (i.e.,Cysview), enabling physicians to detect lesions in the bladder. This improves both diagnosis and treatment of this disease, and may lead to improved survival.
“The availability of Blue Light Cystoscopy is in keeping with DMC Sinai-Grace Hospital’s commitment to advancing care for our patients in and around Detroit with the best tools available,” said Ranko Miocinovic, M.D., DMC’s Director of Urologic Robotic Surgery and leader of Sinai-Grace’s urologic oncology program. “With Cysview, identifying bladder cancer means improved visibility of the tumor, resulting in the ability to remove the entire tumor, thus preventing tumor recurrence. Blue light technology helps turn cancerous cells fluorescent—taking us one step further in the cure. This technology adds another dimension to our urologic robotic oncology program.”
More than 70,000 people in the US were diagnosed with cancer of the bladder in 2009, and an estimated 14,000 Americans died from the disease last year, according to the National Cancer Institute. Bladder cancer is the fourth most common type of cancer in men, and the eighth most common in women. Bladder cancer is also one of the most deadly urologic cancers so early detection is critical. Smoking is the most likely cause of bladder cancer. The most common initial sign of the disease is blood in the urine, which calls for urine cytology (tests performed on cells in urine to detect disease), cystoscopy and further radiologic evaluation.